Adaptive Biotechnologies posts Q3 profit and lifts full‑year MRD revenue outlook

Adaptive Biotechnologies reported third‑quarter 2026 revenue of $83.9 million and GAAP net income of $2.9 million, delivering diluted EPS of $0.02. The company raised its full‑year MRD revenue guidance to $276 million‑$286 million, up from the prior $268 million range. Management highlighted strong clinical‑testing volume growth and the impact of updated NCCN guidelines on clonoSEQ adoption.

The higher MRD revenue outlook signals increased future cash flow for the business, which could improve valuation metrics for shareholders (the company says the guidance reflects stronger clinical volumes). The quarter’s profitability marks the first GAAP profit in the year, indicating progress toward sustainable earnings.

  • 1Q3 2026 revenue was $83.9 million.
  • 2GAAP diluted EPS for the quarter was $0.02.
  • 3GAAP net income attributable to Adaptive was $2.9 million.
  • 4Full‑year MRD revenue guidance was raised to $276 million‑$286 million.
  • 5Clinical testing volume grew 46% year‑over‑year, and clonoSEQ tests increased 10% sequentially.
  • 6U.S. average selling price (ASP) for clonoSEQ was $1,380 in Q3, flat sequentially.
  • Material 1 projected revenue of $71.6 million and a loss of $0.09 per share, which differs from the actual $83.9 million revenue and $0.02 EPS reported.

Sources